Research peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
== Unusual presentations of organizing pneumonia == While patchy bilateral disease is typical, there are unusual variants of organizing pneumonia where it may appear as multiple nodules or masses. One rare presentation, focal organizing pneumonia, may be indistinguishable from lung cancer based on imaging alone, requiring biopsy or surgical resection to make the diagnosis.
== Further reading == "Electronic nicotine delivery systems" (PDF). World Health Organization. 21 July 2014. pp. 1–13. Linda Bauld; Kathryn Angus; Marisa de Andrade (May 2014). "E-cigarette uptake and marketing" (PDF). Public Health England. UK. pp. 1–19. McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). Public Health England. UK. pp. 1–243. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). Public Health England. UK. pp. 1–113. National Academies of Sciences, Engineering, and Medicine; et al. (Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems) (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes. Washington, DC: National Academies Press. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. Retrieved 15 January 2023. Summary National Center for Chronic Disease Prevention Health Promotion (US) Office on Smoking Health (2014). The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Surgeon General of the United States. pp. 1–943. PMID 24455788. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
In situ is a Latin phrase meaning 'in the place' or 'on site', derived from in ('in') and situ (ablative of situs, lit. 'place'). The term refers to studying or working with something in its natural or original location rather than moving it elsewhere. This approach preserves environmental factors and relationships that might be lost when materials or specimens are relocated to controlled settings. In comparison, ex situ ('out of the place') methods involve removing materials or specimens for study, preservation, or modification under controlled conditions, often at the expense of their original context. The earliest recorded use of in situ in English dates back to the mid-17th century. Its use in scientific literature expanded from the late 19th century onward, beginning in medicine and engineering, and later spreading to a wide range of disciplines. The natural sciences typically use in situ methods to study phenomena in their original context. In geology, field studies of soil composition and rock formations may provide direct insights into Earth's processes. Biologists observe organisms in their natural habitats to understand behaviors and ecological interactions that cannot be reproduced in a laboratory. In chemistry and experimental physics, in situ techniques make it possible to watch substances and reactions as they occur, capturing transient phenomena in real time. The scope of in situ methods extends into applied sciences and the humanities. In aerospace engineering, in situ inspections and monitoring systems evaluate performance without interrupting operations.
== Patent infringement lawsuit == In 2002, MDS (at that time owner of SCIEX) and joint venture partner Applied Biosystems, won a $52.6 million judgement against Micromass UK for infringement of U.S. Patent No. 4,963,736 that describes a method of ion focusing using RF fields and gas collisions.
While the Ottoman authorities pursued a divide-and-rule strategy, various European powers established alliances with the various religious groups in the region. The French established an alliance with the Lebanese Christians, while the Druze formalized an alliance with the British, allowing them to send Protestant missionaries into the region. The increasing tensions led to an outbreak of conflict between Christians and Druzes as early as May 1845. Consequently, the European great powers requested for the Ottoman sultan to establish order in Lebanon, and he attempted to do so by establishing a new council in each of the districts. Composed of members of the various religious communities, the councils were intended to assist the deputy governor. Economic and demographic factors also played a role in undermining the peaceful coexistence of the Druze and Christian in this period. The Maronites benefited from the advantages of a modernising and expanding economy, built with French assistance, which was disproportionately accrued to them. Lebanese Christian wealth prospered because of connections with Europe. Additionally, the Maronite population had, over the span of only a few decades, dramatically overtaken that of the Druze. Numerically and commercially; Christians posed a threat to the traditional landlords Druze elite.
Sources: en.wikipedia.org
May improve mood Strengthens and enlarges the heart muscle, to improve its pumping efficiency and reduce the resting heart rate, known as aerobic conditioning May improve circulation efficiency and reduce blood pressure May help maintain independence in later life Increases the total number of red blood cells in the body, facilitating transport of oxygen Improves mental health, including reducing stress and lowering the risk of depression, as well as increased cognitive capacity. Increases the synthesis of brain-derived neurotrophic factor (BDNF), which is thought to contribute to the cognitive benefits of regular exercise. Slightly reduced depression may also be observed, especially if aerobic exercises are used as additional treatment for patients with a hematological malignancy Reduces the risk for diabetes (One meta-analysis has shown, from multiple conducted studies, that aerobic exercise does help lower Hb A1Clevels for type 2 diabetics.) Moderates the risk of death due to cardiovascular problems Promotes weight loss Reduces the risk of osteoporosis May improve episodic memory
==== FAD ==== Flavin adenine dinucleotide in its oxidized form, FAD is a cofactor of flavoprotein oxidoreductase enzymes. Flavoprotein pyridine nucleotide cytochrome reductases, including FAD catalyse the interchange of reducing equivalents (H+ or electrons). Initial electron donors and final electron acceptors comprise single electron carriers and two electron carrying nicotinamide dinucleotides respectively.
== SUMO attachment (SUMOylation) == SUMO attachment to its target is similar to that of ubiquitin (as it is for the other ubiquitin-like proteins such as NEDD 8). The SUMO precursor has some extra amino acids that need to be removed, therefore a C-terminal peptide is cleaved from the SUMO precursor by a protease (in human these are the SENP proteases or Ulp1 in yeast) to reveal a di-glycine motif. The obtained SUMO then becomes bound to an E1 enzyme (SUMO Activating Enzyme (SAE)) which is a heterodimer (subunits SAE1 and SAE2). It is then passed to an E2, which is a conjugating enzyme (Ubc9). Finally, one of a small number of E3 ligating proteins attaches it to the protein. In budding yeast, there are four SUMO E3 proteins, Cst9, Mms21, Siz1 and Siz2. While in ubiquitination an E3 is essential to add ubiquitin to its target, evidence suggests that the E2 is sufficient in SUMOylation as long as the consensus sequence is present. It is thought that the E3 ligase promotes the efficiency of SUMOylation and in some cases has been shown to direct SUMO conjugation onto non-consensus motifs. E3 enzymes can be largely classed into PIAS proteins, such as Mms21 (a member of the Smc5/6 complex) and Pias-gamma and HECT proteins. On Chromosome 17 of the human genome, SUMO2 is near SUMO1+E1/E2 and SUMO2+E1/E2, among various others. Some E3's, such as RanBP2, however, are neither. Recent evidence has shown that PIAS-gamma is required for the SUMOylation of the transcription factor yy1 but it is independent of the zinc-RING finger (identified as the functional domain of the E3 ligases).
It has been found that the addition of nanomaterials in bulk materials substantially increases their adhesive capabilities by increasing their strength through various bonding mechanisms. Nanomaterials dimension approaches zero, which means that the fraction of the particle's surface to overall atoms increases. Along with surface effects, the movement of nanoparticles also plays a role in dictating their mechanical properties such as shearing capabilities. The movement of particles can be observed under TEM. For example, the movement behavior of MoS2 nanoparticles dynamic contact was directly observed in situ which led to the conclusion that fullerenes can shear via rolling or sliding. However, observing these properties is again a very complicated process due to multiple contributing factors. Applications specific to Mechanical Properties:
Sources: en.wikipedia.org
=== Ebola === After initial studies by the Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, US) in cell culture models, on 6 October 2014, Chimerix received an FDA authorization for emergency investigational new drug applications of brincidofovir for the treatment of Ebola virus disease. Brincidofovir was administered to the first patient diagnosed in the Ebola virus disease outbreak in the US in 2014. The patient was given the drug starting six days after hospital admission when he was already critically ill; he died four days later. Brincidofovir was also given to Ebola patient Ashoka Mukpo at the Nebraska Medical Center, who had developed the disease and then was pronounced Ebola-free and released from the center on 22 October 2014. In October 2014, Chimerix reported it had been given approval by the FDA to start Phase 2 trials in patients infected with ebolaviruses for brincidofovir's safety, tolerability, and efficacy. Organised by a team of scientists at the University of Oxford, including Peter Horby, Jake Dunning, Laura Merson and Trudie Lang, a trial commenced during January 2015 in Liberia, but was subsequently discontinued. Because of a lack of suitable subjects in Liberia, Oxford University and Médecins Sans Frontières planned to extend the trial to Sierra Leone, where there were still Ebola cases; but on 30 January 2015, the manufacturer decided to withdraw support for the trial and end discussion of future trials.
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. The drug is currently being studied for its potential use in the treatment of Parkinson's disease.
intrinsically disordered protein (IDP) A protein (or a region or domain within a protein) that lacks any distinct, fixed three-dimensional structure or organization under physiological conditions, instead changing continuously and randomly between multiple transient conformational states rather than folding into any one stable conformation, especially in the absence of specific macromolecular interaction partners. The majority of eukaryotic proteins contain domains with intrinsic structure alongside unstructured domains. Peptide sequences lacking intrinsic order are generally characterized by high proportions of charged and hydrophilic amino acids and low proportions of hydrophobic amino acids, making them inherently flexible, accessible, and modifiable, which allows the same peptide sequence to have distinct functions across a wide variety of biochemical circumstances. They are frequently enriched in binding motifs and are common targets of post-translational modifications, giving them important roles in cell signaling pathways and as hubs in protein complexes.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.